



CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115,

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGNI PAL PATIENT ID: SHIVF02059028

ACCESSION NO: 0028WA000653 AGE: 32 Years SEX: Female ABHA NO:

RECEIVED: 25/01/2023 09:16 31/01/2023 12:07 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Biological Reference Interval Results Units <u>Final</u>

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

BLOOD COUNTS,EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	12.6		12.0 - 15.0	g/dL
METHOD : SPECTROPHOTOMETRY				<i>J</i> ,
RED BLOOD CELL (RBC) COUNT	4.41		3.8 - 4.8	mil/µL
METHOD : ELECTRICAL IMPEDANCE				
WHITE BLOOD CELL (WBC) COUNT	7.20		4.0 - 10.0	thou/µL
METHOD: ELECTRICAL IMPEDANCE				
PLATELET COUNT	133	Low	150 - 410	thou/µL
METHOD: ELECTRICAL IMPEDANCE				
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	39.2		36.0 - 46.0	%
METHOD: CALCULATED PARAMETER				
MEAN CORPUSCULAR VOLUME (MCV)	88.9		83.0 - 101.0	fL
METHOD: DERIVED/COULTER PRINCIPLE				
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	28.6		27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER				
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER	32.2		31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	14.7	High	11.6 - 14.0	%
METHOD : DERIVED/COULTER PRINCIPLE				
MENTZER INDEX	20.2			
METHOD: CALCULATED PARAMETER				
MEAN PLATELET VOLUME (MPV)	12.4	High	6.8 - 10.9	fL
METHOD : DERIVED/COULTER PRINCIPLE				
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	56		40 - 80	%
METHOD: VCS TECHNOLOGY/ MICROSCOPY				
LYMPHOCYTES	33		20 - 40	%
METHOD: VCS TECHNOLOGY/ MICROSCOPY				
MONOCYTES	8		2.0 - 10.0	%
METHOD: VCS TECHNOLOGY/ MICROSCOPY				
EOSINOPHILS	3		1.0 - 6.0	%
METHOD: VCS TECHNOLOGY/ MICROSCOPY				
BASOPHILS	0		0 - 1	%



METHOD: VCS TECHNOLOGY/ MICROSCOPY

Page 1 Of 14 Scan to View Report

Scan to View Details





CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030

DELHI INDIA 8800465156

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115,

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGNI PAL PATIENT ID: SHIVF02059028

ACCESSION NO: 0028WA000653 AGE: 32 Years SEX: Female ABHA NO:

REPORTED: RECEIVED: 25/01/2023 09:16 31/01/2023 12:07 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference Interva	l Units
ABSOLUTE NEUTROPHIL COUNT	4.00		2.0 - 7.0	thou/µL
METHOD: CALCULATED PARAMETER				
ABSOLUTE LYMPHOCYTE COUNT	2.40		1.0 - 3.0	thou/µL
METHOD: CALCULATED PARAMETER				
ABSOLUTE MONOCYTE COUNT	0.60		0.2 - 1.0	thou/µL
METHOD: CALCULATED PARAMETER				
ABSOLUTE EOSINOPHIL COUNT	0.22		0.02 - 0.50	thou/µL
METHOD: CALCULATED PARAMETER				
ABSOLUTE BASOPHIL COUNT	0.00	Low	0.02 - 0.10	thou/µL
METHOD: CALCULATED PARAMETER				
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.7			
METHOD: CALCULATED PARAMETER				
ERYTHROCYTE SEDIMENTATION RATE BLOOD	(ESR),WHOLE			
E.S.R	27	High	< 20	mm at 1 hr
METHOD: MODIFIED WESTERGREN METHOD BY AUTO	MATED ANALYSER			
GLUCOSE FASTING, FLUORIDE PLASMA	1			
FBS (FASTING BLOOD SUGAR)	81		74 - 106	mg/dL
METHOD: HEXOKINASE				
GLYCOSYLATED HEMOGLOBIN(HBA1C) BLOOD), EDTA WHOLE			
HBA1C	5.0		Non-diabetic Adult < 5.7 Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
METHOD: HPLC	06.0		. 116.0	
ESTIMATED AVERAGE GLUCOSE(EAG)	96.8		< 116.0	mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA				
PPBS(POST PRANDIAL BLOOD SUGAR)	105		Non-Diabetes 70 - 140	mg/dL
METHOD: HEXOKINASE				
LIPID PROFILE, SERUM				
CHOLESTEROL, TOTAL	217	High	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL

METHOD: CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE









CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

NEW DELHI 110030 DELHI INDIA 8800465156

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115,

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGNI PAL PATIENT ID: SHIVF02059028

ACCESSION NO: 0028WA000653 AGE: 32 Years SEX: Female ABHA NO:

REPORTED: RECEIVED: 25/01/2023 09:16 31/01/2023 12:07 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference Interv	al Units
TRIGLYCERIDES	67		< 150 Normal 150 - 199 Borderline High 200 - 499 High >/= 500 Very High	mg/dL
METHOD : ENZYMATIC, END POINT	90	High	< 40 Low	ma/dl
HDL CHOLESTEROL	80	nigii	< 40 Low >/=60 High	mg/dL
METHOD: DIRECT MEASURE POLYMER-POLYANION			-	
CHOLESTEROL LDL	124	High	< 100 Optimal 100 - 129 Near or above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL
NON HDL CHOLESTEROL METHOD : CALCULATED PARAMETER	137	High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
VERY LOW DENSITY LIPOPROTEIN	13.4		Desirable value :	mg/dL
VERT LOW BENGITT ENGINEETEN	13.1		10 - 35	mg/ aL
CHOL/HDL RATIO	2.7	Low	3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO	1.6		0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate >6.0 High Risk	Risk
Interpretation(s)				
LIVER FUNCTION PROFILE, SERUM				
BILIRUBIN, TOTAL	0.26		UPTO 1.2	mg/dL
METHOD: DIAZONIUM ION, BLANKED (ROCHE)				
BILIRUBIN, DIRECT METHOD: DIAZOTIZATION	0.09		0.00 - 0.30	mg/dL
BILIRUBIN, INDIRECT METHOD: CALCULATED PARAMETER	0.17		0.00 - 0.60	mg/dL
TOTAL PROTEIN	7.7		6.6 - 8.7	g/dL
METHOD : BIURET, SERUM BLANK, ENDPOINT	, , ,		0.0 0.7	9, 4L
ALBUMIN	4.9		3.97 - 4.94	g/dL
METHOD : BROMOCRESOL GREEN	5			3/ ~-



Page 3 Of 14





CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115,

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGNI PAL PATIENT ID: SHIVF02059028

ACCESSION NO: 0028WA000653 AGE: 32 Years SEX: Female ABHA NO:

REPORTED: RECEIVED: 25/01/2023 09:16 31/01/2023 12:07 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference	Interval Units
GLOBULIN METHOD : CALCULATED DADAMETER	2.8		2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
METHOD : CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO	1.8		1.0 - 2.0	RATIO
METHOD : CALCULATED PARAMETER				
ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD: UV WITHOUT P5P	23		0 - 32	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: UV WITHOUT P5P	23		0 - 31	U/L
ALKALINE PHOSPHATASE METHOD: PNPP, AMP BUFFER-IFCC	89		35 - 105	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: G-GLUTAMYL-CARBOXY-NITROANILIDE-IFCC	16		5 - 36	U/L
LACTATE DEHYDROGENASE METHOD: L TO P, IFCC	157		135 - 214	U/L
BLOOD UREA NITROGEN (BUN), SERUM				
BLOOD UREA NITROGEN METHOD: UREASE - UV	13		6 - 20	mg/dL
CREATININE, SERUM				
CREATININE	0.69		0.50 - 0.90	mg/dL
METHOD : ALKALINE PICRATE-KINETIC				
BUN/CREAT RATIO				
BUN/CREAT RATIO	18.84	High	5.00 - 15.00	
METHOD: CALCULATED PARAMETER				
URIC ACID, SERUM				
URIC ACID	5.6		2.4 - 5.7	mg/dL
METHOD: URICASE, COLORIMETRIC				
TOTAL PROTEIN, SERUM				
TOTAL PROTEIN	7.7		6.6 - 8.7	g/dL
METHOD: BIURET, SERUM BLANK, ENDPOINT				
ALBUMIN, SERUM				
ALBUMIN	4.9		3.97 - 4.94	g/dL
METHOD: BROMOCRESOL GREEN				
CLOBILITA				

GLOBULIN



Page 4 Of 14





CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115,

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGNI PAL PATIENT ID: SHIVF02059028

ACCESSION NO: 0028WA000653 AGE: 32 Years SEX: Female ABHA NO:

REPORTED: RECEIVED: 25/01/2023 09:16 31/01/2023 12:07 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

GLOBULIN 2.8 2.8 2.0 4.0 Neonates - Pre Mature: 0.29 - 1.04 METHOD: CALCULATED PARAMETER ELECTROLYTES (NA/K/CL), SERUM SODIUM, SERUM METHOD: ISE INDIRECT POTASSIUM, SERUM METHOD: ISE INDIRECT CHLORIDE, SERUM METHOD: ISE INDIRECT CHLORIDE, SERUM METHOD: SERINDIRECT Interpretation(s) PHYSICAL EXAMINATION, URINE COLOR METHOD: VISUAL APPEARANCE METHOD: VISUAL CHEMICAL EXAMINATION, URINE CHEMICAL EXAMINATIO	Test Report Status <u>Final</u>	Results	Biological Reference Interv	val Units
ELECTROLYTES (NA/K/CL), SERUM SODIUM, SERUM METHOD: ISE INDIRECT POTASSIUM, SERUM METHOD: ISE INDIRECT CHLORIDE, SERUM METHOD: ISE INDIRECT INTERPRETATION METHOD: ISE INDIRECT THE PYPETATION METHOD: ISE INDIRECT THE PYPETATION METHOD: ISE INDIRECT PHYSICAL EXAMINATION, URINE COLOR METHOD: VISUAL APPEARANCE METHOD: VISUAL APPEARANCE METHOD: VISUAL APPEARANCE METHOD: VISUAL METHOD: SUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY METHOD: PACHANGE OF PRETREATED POLYELECTROLYTES PROTEIN METHOD: PROTEIN- ERROR INDICATOR METHOD: ROTEIN- ERROR INDICATOR METHOD: SOLIDAS-PEROXIDASE REACTION METHOD: CACTOACETIC REACTION WITH NITROPRUSSIDE METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: DIAZOTIZATION WE HORD INDICATOR INTRATE TO NITIRATE TO	GLOBULIN	2.8	Neonates - Pre Mature:	g/dL
SODIUM, SERUM METHOD: ISE INDIRECT POTASSIUM, SERUM METHOD: ISE INDIRECT CHLORIDE, SERUM METHOD: ISE INDIRECT CHLORIDE, SERUM METHOD: ISE INDIRECT INTERPRETATION, URINE COLOR METHOD: VISUAL APPEARANCE METHOD: VISUAL CHEMICAL EXAMINATION, URINE PH 6.0. METHOD: VISUAL CHEMICAL EXAMINATION, URINE PH 6.0. METHOD: OUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY METHOD: PKA CHANGE OF PRETREATED POLYELECTROLYTES PROTEIN METHOD: PROTEIN- ERROR INDICATOR METHOD: OXIDASE-PEROXIDASE REACTION KETONES METHOD: OXIDASE-PEROXIDASE REACTION KETONES METHOD: ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD METHOD: PROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN METHOD: DETECTED NOT DETECTED				
METHOD: ISE INDIRECT POTASSIUM, SERUM METHOD: ISE INDIRECT CHLORIDE, SERUM METHOD: ISE INDIRECT Interpretation(s) PHYSICAL EXAMINATION, URINE COLOR METHOD: VISUAL APPEARANCE METHOD: VISUAL CHEMICAL EXAMINATION, URINE PH 6.0 6.0 4.7 - 7.5 METHOD: DUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY METHOD: PKA CHANGE OF PRETREATED POLYELECTROLYTES PROTEIN METHOD: PROTEIN- ERROR INDICATOR METHOD: OXIDASE-PEROXIDASE REACTION METHOD: OXIDASE-PEROXIDASE REACTION METHOD: APPEARANCE METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: OXIDASE-PEROXIDASE REACTION METHOD: OXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BLILOUD METHOD: PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BLILOUD METHOD: PROTEIN- ERROR INDICATOR METHOD: DIAZOTIZATION UROBALLINOGEN METHOD: MOT DETECTED NOT DETE				
POTASSIUM, SERUM METHOD: ISE INDIRECT CHLORIDE, SERUM METHOD: ISE INDIRECT Interpretation(s) PHYSICAL EXAMINATION, URINE COLOR METHOD: VISUAL APPEARANCE METHOD: VISUAL APPEARANCE METHOD: VISUAL APPEARANCE METHOD: SUSUAL CHEMICAL EXAMINATION, URINE CHEMICAL EXAMINATION, URINE PH 6.0.		138	136 - 145	mmol/L
METHOD: ISE INDIRECT CHLORIDE, SERUM METHOD: ISE INDIRECT INterpretation(s) PHYSICAL EXAMINATION, URINE COLOR PALE YELLOW METHOD: VISUAL APPEARANCE SLIGHTLY HAZY METHOD: VISUAL APPEARANCE HORDING SPECIAL EXAMINATION, URINE CHEMICAL EXAMINATION, URINE CHEMICAL EXAMINATION, URINE CHEMICAL EXAMINATION, URINE PH 6.0 4.7 - 7.5 METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY < <=1.005 1.003 - 1.035 PROTEIN NOT DETECTED NOT DETECTED METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR GLUCOSE NOT DETECTED NOT DETECTED METHOD: OXIDASE-PEROXIDASE REACTION KETONES NOT DETECTED NOT DETECTED METHOD: ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD NOT DETECTED NOT DETECTED METHOD: DEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN NOT DETECTED NOT DETECTED METHOD: DIAZOTIZATION UROBLINOGEN METHOD: MODIFIED ERRICLE REACTION MITRITE NORMAL NORMAL NORMAL WETHOD: MODIFIED ERRICLE REACTION NITRITE NOT DETECTED NOT DETECTED NOT DETECTED				
CHLORIDE, SERUM METHOD: ISE INDIRECT Interpretation(s) PHYSICAL EXAMINATION, URINE COLOR METHOD: VISUAL APPEARANCE METHOD: VISUAL APPEARANCE METHOD: VISUAL CHEMICAL EXAMINATION, URINE CHEMICAL EXAMINATION, URINE PH 6.0 6.0 4.7 - 7.5 METHOD: POLICATOR PRINCIPLE SPECIFIC GRAVITY METHOD: PORTEIN- ERROR INDICATOR PRINCIPLE SPECIFIC GRAVITY METHOD: PORTEIN- ERROR INDICATOR METHOD: PORTEIN- ERROR INDICATOR METHOD: OXIDASE-PEROXIDASE REACTION KETONES METHOD: ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD METHOD: PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN METHOD: PORTEIN- ERROR INDICATION METHOD: PORTEIN- ERROR INDICATOR METHOD: OXIDASE-LIKE ACTIVITY OF HEMOGLOBIN METHOD: OXIDASE-LIKE ACTIVITY OF HEMOGLOBIN METHOD: MODIFIED ERROR INDICATION MITRITE METHOD: MODIFIED ERROR INDICATION NOT DETECTED NO	POTASSIUM, SERUM	4.03	3.5 - 5.1	mmol/L
METHOD: ISE INDIRECT Interpretation(s) PHYSICAL EXAMINATION, URINE COLOR PALE YELLOW METHOD: VISUAL APPEARANCE SLIGHTLY HAZY METHOD: VISUAL CHEMICAL EXAMINATION, URINE PH 6.0 4.7 - 7.5 METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY <=1.005 1.003 - 1.035 METHOD: PKA CHANGE OF PRETREATED POLYELECTROLYTES PROTEIN NOT DETECTED NOT DETECTED METHOD: PROTEIN- ERROR INDICATOR GLUCOSE NOT DETECTED NOT DETECTED METHOD: OXIDASE-PEROXIDASE REACTION KETONES NOT DETECTED NOT DETECTED METHOD: ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD NOT DETECTED NOT DETECTED METHOD: PROTEIN- ERROR INDICATOR KETONES NOT DETECTED NOT DETECTED METHOD: ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD NOT DETECTED NOT DETECTED METHOD: PROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN NOT DETECTED NOT DETECTED METHOD: DIAZOTIZATION UROBILINOGEN NORMAL NORMAL METHOD: MODIFIED EHRLICH REACTION NITRITE NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED				
Interpretation(s) PHYSICAL EXAMINATION, URINE COLOR PALE YELLOW METHOD: VISUAL APPEARANCE SLIGHTLY HAZY METHOD: VISUAL CHEMICAL EXAMINATION, URINE PH 6.0 4.7 - 7.5 METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY < <=1.005 1.003 - 1.035 METHOD: PROTEIN- ERROR INDICATOR METHOD: PROTEIN- ERROR INDICATOR METHOD: OXIDASE-PEROXIDASE REACTION METHOD: OXIDASE-PEROXIDASE REACTION KETONES NOT DETECTED NOT DETECTED METHOD: ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD NOT DETECTED NOT DETECTED METHOD: DETECTED NOT DETECTED METHOD: DETECTED NOT DETECTED METHOD: OXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN NOT DETECTED NOT DETECTED METHOD: DIAZOTIZATION UROBILINOGEN NORMAL NORMAL METHOD: MODIFIED EHRLICH REACTION		100	98 - 107	mmol/L
PHYSICAL EXAMINATION, URINE COLOR PALE YELLOW METHOD: VISUAL APPEARANCE SLIGHTLY HAZY METHOD: VISUAL CHEMICAL EXAMINATION, URINE PH 6.0 4.7 - 7.5 METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY < =1.005 1.003 - 1.035 METHOD: PKA CHANGE OF PRETREATED POLYELECTROLYTES PROTEIN NOT DETECTED NOT DETECTED METHOD: PROTEIN- ERROR INDICATOR GLUCOSE NOT DETECTED NOT DETECTED METHOD: OXIDASE-PEROXIDASE REACTION KETONDES NOT DETECTED NOT DETECTED METHOD: PROTEITION WITH NITROPRUSSIDE BLOOD NOT DETECTED NOT DETECTED METHOD: PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILLIUBIN NOT DETECTED NOT DETECTED METHOD: DIAZOTIZATION UROBILINOGEN NORMAL NORMAL METHOD: MODIFIED EHRLICH REACTION METHOD: MODIFIED EHRLICH REACTION METHOD: MODIFIED EHRLICH REACTION NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NOT DETECTED				
COLOR METHOD: VISUAL APPEARANCE METHOD: VISUAL CHEMICAL EXAMINATION, URINE PH 6.0 METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY METHOD: PKA CHANGE OF PRETREATED POLYELECTROLYTES PROTEIN METHOD: PROTEIN- ERROR INDICATOR METHOD: OXIDASE-PEROXIDASE REACTION KETODE: ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD METHOD: ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD METHOD: PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILLRUBIN METHOD: DIAZOTIZATION WETHOD: MODIFIED EHRLICH REACTION METHOD: MODIFIED EHRLICH REACTION NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NORMAL	Interpretation(s)			
METHOD : VISUAL APPEARANCE METHOD : VISUAL CHEMICAL EXAMINATION, URINE PH 6.0 4.7 - 7.5 METHOD : DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY AETHOD : PRA CHANGE OF PRETREATED POLYELECTROLYTES PROTEIN METHOD : PROTEIN- ERROR INDICATOR GLUCOSE METHOD : OXIDASE-PEROXIDASE REACTION KETONES METHOD : ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD METHOD : PROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN METHOD : DAZOTIZATION UROBILINOGEN METHOD : DAZOTIZATION UROBILINOGEN METHOD : MODIFIED EHRLICH REACTION NOT DETECTED	PHYSICAL EXAMINATION, URINE			
APPEARANCE METHOD: VISUAL CHEMICAL EXAMINATION, URINE PH 6.0 6.0 4.7 - 7.5 METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY < <=1.005 1.003 - 1.035 METHOD: PKA CHANGE OF PRETREATED POLYELECTROLYTES PROTEIN NOT DETECTED NOT DETECTED METHOD: PROTEIN- ERROR INDICATOR GLUCOSE NOT DETECTED NOT DETECTED METHOD: OXIDASE-PEROXIDASE REACTION KETONES NOT DETECTED NOT DETECTED METHOD: ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD NOT DETECTED NOT DETECTED METHOD: PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN NOT DETECTED NOT DETECTED METHOD: DIAZOTIZATION UROBILINOGEN NORMAL NORMAL METHOD: MODIFIED EHRLICH REACTION MITRITE NOT DETECTED NOT DETECTED METHOD: MODIFIED EHRLICH REACTION NOT DETECTED NOT DETECTED MOT DETECTED NOT DETECTED NORMAL	COLOR	PALE YELLOW		
METHOD : VISUAL CHEMICAL EXAMINATION, URINE PH 6.0 4.7 - 7.5 METHOD : DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY < <=1.005 1.003 - 1.035 METHOD : PKA CHANGE OF PRETREATED POLYELECTROLYTES PROTEIN NOT DETECTED NOT DETECTED METHOD : PROTEIN- ERROR INDICATOR GLUCOSE NOT DETECTED NOT DETECTED METHOD : OXIDASE-PEROXIDASE REACTION KETONES NOT DETECTED NOT DETECTED METHOD : ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD NOT DETECTED NOT DETECTED METHOD : PROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN NOT DETECTED NOT DETECTED METHOD : DIAZOTIZATION UROBILINOGEN NORMAL NORMAL METHOD : MODIFIED EHRLICH REACTION NITRITE NOT DETECTED NOT DETECTED MOT DETECTED NOT DETECTED	METHOD: VISUAL			
CHEMICAL EXAMINATION, URINE PH 6.0 6.0 4.7 - 7.5 METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY < =1.005 1.003 - 1.035 METHOD: PKA CHANGE OF PRETREATED POLYELECTROLYTES PROTEIN NOT DETECTED NOT DETECTED METHOD: PROTEIN- ERROR INDICATOR GLUCOSE NOT DETECTED NOT DETECTED METHOD: OXIDASE-PEROXIDASE REACTION KETONES NOT DETECTED NOT DETECTED METHOD: ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD NOT DETECTED NOT DETECTED METHOD: PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN NOT DETECTED NOT DETECTED METHOD: DIAZOTIZATION UROBILINOGEN NORMAL NORMAL METHOD: MODIFIED EHRLICH REACTION NITRITE NOT DETECTED NOT DETECTED METHOD: CONVERTION OF NITRATE TO NITRITE	APPEARANCE	SLIGHTLY HAZY		
PH 6.0 4.7 - 7.5 METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY <=1.005 1.003 - 1.035 METHOD: PKA CHANGE OF PRETREATED POLYELECTROLYTES PROTEIN NOT DETECTED NOT DETECTED METHOD: PROTEIN- ERROR INDICATOR GLUCOSE NOT DETECTED NOT DETECTED METHOD: OXIDASE-PEROXIDASE REACTION KETONES NOT DETECTED NOT DETECTED METHOD: ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD NOT DETECTED NOT DETECTED METHOD: PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN NOT DETECTED NOT DETECTED METHOD: DIAZOTIZATION UROBILINOGEN NORMAL NORMAL METHOD: MODIFIED EHRLICH REACTION NITRITE NOT DETECTED NOT DETECTED METHOD: CONVERTION OF NITRATE TO NITRITE	METHOD: VISUAL			
METHOD : DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY <=1.005 1.003 - 1.035 METHOD : PKA CHANGE OF PRETREATED POLYELECTROLYTES PROTEIN NOT DETECTED NOT DETECTED METHOD : PROTEIN- ERROR INDICATOR GLUCOSE NOT DETECTED NOT DETECTED METHOD : OXIDASE-PEROXIDASE REACTION KETONES NOT DETECTED NOT DETECTED METHOD : ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD NOT DETECTED NOT DETECTED METHOD : PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN NOT DETECTED NOT DETECTED METHOD : DIAZOTIZATION UROBILINOGEN NORMAL NORMAL METHOD : MODIFIED EHRLICH REACTION NITRITE NOT DETECTED NOT DETECTED METHOD : CONVERTION OF NITRATE TO NITRITE	CHEMICAL EXAMINATION, URINE			
SPECIFIC GRAVITY METHOD: PKA CHANGE OF PRETREATED POLYELECTROLYTES PROTEIN METHOD: PROTEIN- ERROR INDICATOR GLUCOSE METHOD: OXIDASE-PEROXIDASE REACTION KETONES METHOD: ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD METHOD: PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN METHOD: DIAZOTIZATION UROBILINOGEN METHOD: MODIFIED EHRLICH REACTION NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NORMAL	PH	6.0	4.7 - 7.5	
METHOD : PKA CHANGE OF PRETREATED POLYELECTROLYTES PROTEIN NOT DETECTED NOT DETECTED METHOD : PROTEIN- ERROR INDICATOR GLUCOSE NOT DETECTED NOT DETECTED METHOD : OXIDASE-PEROXIDASE REACTION KETONES NOT DETECTED NOT DETECTED METHOD : ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD NOT DETECTED NOT DETECTED METHOD : PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN NOT DETECTED NOT DETECTED METHOD : DIAZOTIZATION UROBILINOGEN NORMAL NORMAL METHOD : MODIFIED EHRLICH REACTION NITRITE NOT DETECTED NOT DETECTED METHOD : CONVERTION OF NITRATE TO NITRITE	METHOD: DOUBLE INDICATOR PRINCIPLE			
PROTEIN METHOD: PROTEIN- ERROR INDICATOR GLUCOSE METHOD: OXIDASE-PEROXIDASE REACTION KETONES METHOD: ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD METHOD: PROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN METHOD: DIAZOTIZATION UROBILINOGEN METHOD: MODIFIED EHRLICH REACTION METHOD: MODIFIED EHRLICH REACTION NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED	SPECIFIC GRAVITY	<=1.005	1.003 - 1.035	
METHOD : PROTEIN- ERROR INDICATOR GLUCOSE METHOD : OXIDASE-PEROXIDASE REACTION KETONES METHOD : ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD METHOD : PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN METHOD : DIAZOTIZATION UROBILINOGEN METHOD : MODIFIED EHRLICH REACTION NOT DETECTED	METHOD: PKA CHANGE OF PRETREATED POLYELECTROLYTES			
GLUCOSE METHOD: OXIDASE-PEROXIDASE REACTION KETONES NOT DETECTED NOT DETECTED METHOD: ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD METHOD: PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN METHOD: DIAZOTIZATION UROBILINOGEN METHOD: MODIFIED EHRLICH REACTION NOT DETECTED NOT DETECTED NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NOT DETECTED NOT DETECTED	PROTEIN	NOT DETECTED	NOT DETECTED	
METHOD : OXIDASE-PEROXIDASE REACTION KETONES MOT DETECTED METHOD : ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD METHOD : PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN METHOD : DIAZOTIZATION UROBILINOGEN METHOD : MODIFIED EHRLICH REACTION NOT DETECTED NOT DETECTED NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NOT DETECTED NOT DETECTED NOT DETECTED	METHOD: PROTEIN- ERROR INDICATOR			
KETONES METHOD : ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD METHOD : PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN METHOD : DIAZOTIZATION UROBILINOGEN METHOD : MODIFIED EHRLICH REACTION NOT DETECTED	GLUCOSE	NOT DETECTED	NOT DETECTED	
METHOD : ACETOACETIC REACTION WITH NITROPRUSSIDE BLOOD NOT DETECTED NOT DETECTED METHOD : PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN NOT DETECTED NOT DETECTED METHOD : DIAZOTIZATION UROBILINOGEN NORMAL NORMAL METHOD : MODIFIED EHRLICH REACTION NITRITE NOT DETECTED NOT DETECTED METHOD : CONVERTION OF NITRATE TO NITRITE	METHOD: OXIDASE-PEROXIDASE REACTION			
BLOOD NOT DETECTED NOT DETECTED METHOD : PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN NOT DETECTED NOT DETECTED METHOD : DIAZOTIZATION UROBILINOGEN NORMAL NORMAL METHOD : MODIFIED EHRLICH REACTION NITRITE NOT DETECTED NOT DETECTED METHOD : CONVERTION OF NITRATE TO NITRITE	KETONES	NOT DETECTED	NOT DETECTED	
METHOD : PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN BILIRUBIN METHOD : DIAZOTIZATION UROBILINOGEN METHOD : MODIFIED EHRLICH REACTION NITRITE NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED	METHOD: ACETOACETIC REACTION WITH NITROPRUSSIDE			
BILIRUBIN NOT DETECTED NOT DETECTED METHOD : DIAZOTIZATION UROBILINOGEN NORMAL NORMAL METHOD : MODIFIED EHRLICH REACTION NITRITE NOT DETECTED NOT DETECTED METHOD : CONVERTION OF NITRATE TO NITRITE	BLOOD	NOT DETECTED	NOT DETECTED	
METHOD : DIAZOTIZATION UROBILINOGEN METHOD : MODIFIED EHRLICH REACTION NITRITE METHOD : CONVERTION OF NITRATE TO NITRITE	METHOD: PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN			
UROBILINOGEN NORMAL NORMAL METHOD: MODIFIED EHRLICH REACTION NITRITE NOT DETECTED NOT DETECTED METHOD: CONVERTION OF NITRATE TO NITRITE	BILIRUBIN	NOT DETECTED	NOT DETECTED	
METHOD : MODIFIED EHRLICH REACTION NITRITE NOT DETECTED NOT DETECTED METHOD : CONVERTION OF NITRATE TO NITRITE	METHOD: DIAZOTIZATION			
NITRITE NOT DETECTED NOT DETECTED METHOD: CONVERTION OF NITRATE TO NITRITE		NORMAL	NORMAL	
METHOD: CONVERTION OF NITRATE TO NITRITE	METHOD: MODIFIED EHRLICH REACTION			
		NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED				
	LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	









CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115,

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGNI PAL PATIENT ID: SHIVF02059028

ACCESSION NO: 0028WA000653 AGE: 32 Years SEX: Female ABHA NO:

RECEIVED: 25/01/2023 09:16 31/01/2023 12:07 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference In	terval Units
METHOD FOTEDACE INCOONED ACTIVITY			
METHOD : ESTERASE HYDROLYSIS ACTIVITY			
MICROSCOPIC EXAMINATION, URINE	NOT DETECTED	NOT DETECTED	/LIDE
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
METHOD: MICROSCOPIC EXAMINATION	2.2	0.5	/LIDE
PUS CELL (WBC'S)	2-3	0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION EPITHELIAL CELLS	8-10	0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION	0-10	0-3	/HPF
CASTS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED		
CRYSTALS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED		
BACTERIA	NOT DETECTED	NOT DETECTED	
METHOD: MICROSCOPIC EXAMINATION	NOT BETECTED	No. Beredies	
YEAST	NOT DETECTED	NOT DETECTED	
REMARKS	MICROSCOPIC EXAMINATION DONE ON CENTRIFUGED URINE PLEASE NOTE THAT GRADING OF BACTERIA NEEDS TO BE CORELATED WITH THE CULTURE IN CASE FOUND SIGNIFICANT CLINICALLY. OCCASIONAL BACTERIA/YEAST CELLS SEEN IN MICROSCOPY CAN BE A PART OF SURROUNDING SKIN FLORA ALSO.		
METHOD: MANUAL			
Interpretation(s)			
THYROID PANEL, SERUM			
Т3	118.9	80.00 - 200.00	ng/dL
METHOD : ECLIA	F 00	5.40 .44.40	
T4	5.92	5.10 - 14.10	μg/dL
METHOD: ECLIA	2.420		T11/
TSH (ULTRASENSITIVE)	2.130	Non Pregnant Women 0.27 - 4.20 Pregnant Women 1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15)
METHOD : ECLIA			
Interpretation(s)			
PAPANICOLAOU SMEAR			
SPECIMEN TYPE	Cytology number C-2	207-23	

Cervical cytological preparation

2 smears examined

2014 Bethesda system



REPORTING SYSTEM

Page 6 Of 14 Scan to View Report





CLIENT CODE: C000138361
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115,

CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGNI PAL PATIENT ID: SHIVF02059028

ACCESSION NO: 0028WA000653 AGE: 32 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 25/01/2023 09:16 REPORTED: 31/01/2023 12:07

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

SPECIMEN ADEQUACY Smears are satisfactory for evaluation

MICROSCOPY Endocervical cells/transformation zone component present

Inflammation with reactive cellular changes

INTERPRETATION / RESULT Negative for intraepithelial lesion or malignancy

Comments

Pap smear cytology is a screening test. Corroboration of cytopathologic findings with colposcopic/local examination and ancillary findings is

recommended.

PHYSICAL EXAMINATION, STOOL

COLOUR BROWN

METHOD : GUAIAC METHOD

CONSISTENCY SEMI FORMED

 ${\sf METHOD}: {\sf MANUAL}$

MUCUS ABSENT NOT DETECTED

METHOD : MANUAL

VISIBLE BLOOD ABSENT ABSENT ABSENT

METHOD: MANUAL

ADULT PARASITE NOT DETECTED

METHOD: CONCENTRATION AND MICROSCOPY

CHEMICAL EXAMINATION, STOOL

STOOL PH 6.5

MICROSCOPIC EXAMINATION, STOOL

PUS CELLS 0-1 /hpf

RED BLOOD CELLS NOT DETECTED NOT DETECTED /HPF

METHOD: CONCENTRATION AND MICROSCOPY

CYSTS NOT DETECTED NOT DETECTED

METHOD: CONCENTRATION AND MICROSCOPY

METHOD: CONCENTRATION AND MICROSCOPY

OVA NOT DETECTED

LARVAE NOT DETECTED NOT DETECTED

METHOD: CONCENTRATION AND MICROSCOPY

TROPHOZOITES NOT DETECTED NOT DETECTED

METHOD: CONCENTRATION AND MICROSCOPY

FAT ABSENT
VEGETABLE CELLS ABSENT
CHARCOT LEYDEN CRYSTALS ABSENT

CONCENTRATION METHOD OVA OR CYSTS NOT SEEN



Page 7 Of 14





CLIENT CODE: C000138361
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115,

CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGNI PAL PATIENT ID: SHIVF02059028

ACCESSION NO: 0028WA000653 AGE: 32 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 25/01/2023 09:16 REPORTED: 31/01/2023 12:07

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE A

METHOD: COLUMN AGGLUTINATION TECHOLOGY

RH TYPE POSITIVE

METHOD: COLUMN AGGLUTINATION TECHOLOGY

XRAY-CHEST

»»
BOTH THE LUNG FIELDS ARE CLEAR

»» BOTH THE COSTOPHRENIC AND CARIOPHRENIC ANGELS ARE CLEAR

»» BOTH THE HILA ARE NORMAL

»» CARDIAC AND AORTIC SHADOWS APPEAR NORMAL»» BOTH THE DOMES OF THE DIAPHRAM ARE NORMAL

»» VISUALIZED BONY THORAX IS NORMAL

IMPRESSION NORMAL

TMT OR ECHO

TMT OR ECHO 2D ECHO DONE

ECG

ECG WITHIN NORMAL LIMITS

MEDICAL HISTORY

RELEVANT PRESENT HISTORY

RELEVANT PAST HISTORY

RELEVANT PERSONAL HISTORY

MARRIED 2 CHILD VEG

MENSTRUAL HISTORY (FOR FEMALES) REGULLAR LMP (FOR FEMALES) 1/1/23

RELEVANT FAMILY HISTORY MOTHER DIABTES

OCCUPATIONAL HISTORY JOB

HISTORY OF MEDICATIONS NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.62 mts
WEIGHT IN KGS. 65 Kgs

BMI & Weight Status as follows: kg/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION



Page 8 Of 14





CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHT

NEW DELHI 110030 DELHI INDIA 8800465156

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115,

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGNI PAL PATIENT ID: SHIVF02059028

ACCESSION NO: **0028WA000653** AGE: 32 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 25/01/2023 09:16 REPORTED: 31/01/2023 12:07

REFERRING DOCTOR: CLIENT PATIENT ID: SELF

Test Report Status Results **Biological Reference Interval** Units **Final** MENTAL / EMOTIONAL STATE **NORMAL** PHYSICAL ATTITUDE **NORMAL** GENERAL APPEARANCE / NUTRITIONAL STATUS **HEALTHY BUILT / SKELETAL FRAMEWORK AVERAGE** FACIAL APPEARANCE **NORMAL** SKIN **NORMAL** UPPER LIMB **NORMAL** LOWER LIMB **NORMAL NECK NORMAL** NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER THYROID GLAND NOT ENLARGED CAROTID PULSATION **NORMAL TEMPERATURE NORMAL PULSE** 85/MINUTE, REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID BRUIT RESPIRATORY RATE **NORMAL CARDIOVASCULAR SYSTEM** 120/91 mm/Hg **PERICARDIUM NORMAL** APEX BEAT **NORMAL HEART SOUNDS** S1, S2 HEARD NORMALLY **MURMURS ABSENT** RESPIRATORY SYSTEM SIZE AND SHAPE OF CHEST NORMAL MOVEMENTS OF CHEST SYMMETRICAL

BREATH SOUNDS INTENSITY NORMAL

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS ABSENT

PER ABDOMEN

APPEARANCE NORMAL VENOUS PROMINENCE ABSENT **LIVER** NOT PALPABLE **SPLEEN** NOT PALPABLE

CENTRAL NERVOUS SYSTEM









CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115,

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

REQUESTED. GENERAL PHYSICAL EXAMINATION IS NORMAL."

PATIENT NAME: SHIVANGNI PAL PATIENT ID: SHIVF02059028

ACCESSION NO: 0028WA000653 AGE: 32 Years SEX: Female ABHA NO:

RECEIVED: 25/01/2023 09:16 31/01/2023 12:07 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units
HIGHER FUNCTIONS		NORMAL		
CRANIAL NERVES		NORMAL		
CEREBELLAR FUNCTIO	NS	NORMAL		
SENSORY SYSTEM		NORMAL		
MOTOR SYSTEM		NORMAL		
REFLEXES		NORMAL		
MUSCULOSKELETAL	SYSTEM			
SPINE		NORMAL		
JOINTS		NORMAL		
BASIC EYE EXAMINA	TION			
CONJUNCTIVA		NORMAL		
EYELIDS		NORMAL		
EYE MOVEMENTS		NORMAL		
CORNEA		NORMAL		
DISTANT VISION RIGH	T EYE WITHOUT GLASSES	NORMAL		
DISTANT VISION LEFT	EYE WITHOUT GLASSES	NORMAL		
NEAR VISION RIGHT E	YE WITHOUT GLASSES	NORMAL		
NEAR VISION LEFT EYE	WITHOUT GLASSES	NORMAL		
COLOUR VISION		NORMAL		
BASIC ENT EXAMINA	TION			
EXTERNAL EAR CANAL		NORMAL		
TYMPANIC MEMBRANE		NORMAL		
NOSE		NO ABNORMALITY	DETECTED	
SINUSES		CLEAR		
THROAT		NO ABNORMALITY	DETECTED	
TONSILS		NOT ENLARGED		
SUMMARY				
RELEVANT HISTORY		NOT SIGNIFICANT		
RELEVANT GP EXAMINA	ATION FINDINGS	NOT SIGNIFICANT		
RELEVANT LAB INVEST	TIGATIONS	WITHIN NORMAL L	IMITS	
RELEVANT NON PATHO	LOGY DIAGNOSTICS	NO ABNORMALITIE	S DETECTED	
REMARKS / RECOMMEN	NDATIONS			
		"NO ABNORMALITY	FOUND OUT OF THE DIAGNOSTIC PACKAG	iE "









CLIENT CODE: C000138361

CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHT **NEW DELHI 110030 DELHI INDIA** 8800465156

SRL Ltd

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115,

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGNI PAL PATIENT ID: SHIVF02059028

ACCESSION NO: 0028WA000653 AGE: 32 Years SEX: Female ABHA NO:

RECEIVED: 25/01/2023 09:16 REPORTED: 31/01/2023 12:07 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units **Final**

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading

to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-**TEST DESCRIPTION**:
Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall

(sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging.
Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. **Decreased** in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

REFERENCE:

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLUCOSE FASTING,FLUORIDE PLASMA-**TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. **Decreased in**

Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency, hypopituitarism,diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents.

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2.Diagnosing diabetes.3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- 1.eAG (Estimated average glucose) converts percentage HbAIc to md/dl, to compare blood glucose levels.

 2. eAG gives an evaluation of blood glucose levels for the last couple of months.

 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :



Page 11 Of 14





CLIENT CODE: C000138361

CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHT **NEW DELHI 110030** DELHI INDIA 8800465156

SRL Ltd

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115,

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGNI PAL PATIENT ID: SHIVF02059028

ACCESSION NO: 0028WA000653 AGE: 32 Years SEX: Female ABHA NO:

RECEIVED: 25/01/2023 09:16 REPORTED: 31/01/2023 12:07 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units **Final**

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. II. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results. IV.Interference of hemoglobinopathies in HbA1c estimation is seen in

a. Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
b. Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
c. HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured

clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, kidney failure, hemotytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget""s disease,Rickets,Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia,Malnutrition,Protein deficiency,Wilson"'s disease.GGT is an enzyme found in cell membranes of many tissues mainly in the liver,kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstrom''' disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.Human serum albumin is the most abundant protein in human blood plasma.It is produced in the liver.Albumin constitutes about half of the blood serum protein.Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,

Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)
Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

- Blockage in the urinary tract
- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
 Loss of body fluid (dehydration)
 Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia GravisMuscular dystrophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome

Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum.. Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom"""""""""""" disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc. ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.



Page 12 Of 14







CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 **DELHI INDIA** 8800465156

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115,

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGNI PAL PATIENT ID: SHIVF02059028

ACCESSION NO: 0028WA000653 AGE: 32 Years SEX: Female ABHA NO:

31/01/2023 12:07 DRAWN: RECEIVED: 25/01/2023 09:16 REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units <u>Final</u>

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

MEDICAL

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.









CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI **NEW DELHI 110030** DELHI INDIA 8800465156

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115,

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGNI PAL PATIENT ID: SHIVF02059028

ACCESSION NO: 0028WA000653 AGE: 32 Years SEX: Female ABHA NO:

31/01/2023 12:07 DRAWN: RECEIVED: 25/01/2023 09:16 REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Units **Test Report Status** Results **Final**

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN PENDING

> **End Of Report** Please visit www.srlworld.com for related Test Information for this accession

Dr. Neena Verma, MD (Pathology) **Deputy Lab Head**

Dr. Ravneet Kaur, MD (Microbiology) Head Lab Operation Sr. Microbiologist

Rameet Keun

Dr. Dipti Bisaria, DNB Pathology **Pathologist**

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist



